Advanced search
Publication Cover
Cancer Investigation Volume 40, 2022 - Issue 2
Submit an article Journal homepage
409
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Ahmet Bilicia Department of Medical Oncology, Medical Faculty, Medipol University, Bagcilar, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0443-6966
ORCID Icon,
Mukremin Uysalb Department of Medical Oncology, Medical Faculty, Afyon Kocatepe University, Afyon, TurkeyORCID Iconhttps://orcid.org/0000-0002-8524-0665
ORCID Icon,
Serkan Meneksec Department of Medical Oncology, Manisa State Hospital, Manisa, Turkey
,
Semih Akind Department of Medical Oncology, Medical Faculty, Ege University, Izmir, Turkey
,
Fatih Yildize Department of Medical Oncology, Dr Abdurrahman Yurtarslan Oncology Education and Research Hospital, Ankara, Turkey
,
Merve Turanf Department of Medical Oncology, Medical Faculty, Adnan Menderes University, Aydin, Turkey
,
Sema Sezgin Goksug Department of Medical Oncology, Medical Faculty, Akdeniz University, Antalya, TurkeyORCID Iconhttps://orcid.org/0000-0002-8026-764X
ORCID Icon,
Ismail Beypinarb Department of Medical Oncology, Medical Faculty, Afyon Kocatepe University, Afyon, Turkey
,
Teoman Sakalarh Department of Medical Oncology, Medical Faculty, Erciyes University, Kayseri, Turkey
,
Mustafa Değirmencii Department of Medical Oncology, Izmir Tepecik Education and Research Hospital, Izmir, Turkey
,
Dilek Erdemj Department of Medical Oncology, Medical Faculty, Bahcesehir University, Samsun, Turkey
,
Gul Basarank Department of Medical Oncology, Medical Faculty, Acibadem University, Istanbul, Turkey
,
Omer Fatih Olmeza Department of Medical Oncology, Medical Faculty, Medipol University, Bagcilar, TurkeyORCID Iconhttps://orcid.org/0000-0001-7934-7039
ORCID Icon,
Nilufer Avcil Department of Medical Oncology, Medicana Bursa Hospital, Bursa, Turkey
,
Deniz Turalm Department of Medical Oncology, Bakirkoy Dr Sadi Konuk Education and Research Hospital, Istanbul, Turkey
,
Abdullah Sakinn Department of Medical Oncology, Medical Faculty, Yuzuncuyil University, Van, Turkey
,
Sema Turkero Department of Medical Oncology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey
,
Atakan Demirk Department of Medical Oncology, Medical Faculty, Acibadem University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-1940-4086
ORCID Icon,
Suleyman Temizp Department of Medical Oncology, Kocaeli Acıbadem Hospital, Kocaeli, Turkey
,
Muhammed Ali Kaplanq Department of Medical Oncology, Medical Faculty, Dicle University, Diyarbakir, Turkey
,
Mutlu Doganr Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
,
Ozgur Tanriverdis Department of Medical Oncology, Medical Faculty, Mugla Sitki Kocman University, Mugla, Turkey
,
Irem Bilgetekint Department of Medical Oncology, Medical Faculty, Gazi University, Ankara, Turkey
,
Havva Yesil Cinkiru Department of Medical Oncology, Medical Faculty, Gaziantep University, Gaziantep, Turkey
,
Ozgur Acikgoza Department of Medical Oncology, Medical Faculty, Medipol University, Bagcilar, TurkeyORCID Iconhttps://orcid.org/0000-0003-2715-4002
ORCID Icon,
Semra Paydasv Department of Medical Oncology, Medical Faculty, Cukurova University, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0003-4642-3693
ORCID Icon,
Ruchan Uslud Department of Medical Oncology, Medical Faculty, Ege University, Izmir, Turkey
&
Serdar Turhalw Anadolu Medical Center, Department of Medical Oncology, Istanbul, Turkey
 show all
Pages 199-209 | Received 26 Aug 2021, Accepted 08 Dec 2021, Published online: 22 Dec 2021
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Purpose

This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings.

Methods

Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed.

Results

The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001).

Conclusion

We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients.

Acknowledgments

This study was presented in SABCS, 2018, San Antonio Breast Cancer Symposium, in a poster session. A. Bilici, S. Menekse, S. Akın, M. Degirmenci, O. F. Olmez, N. Avci, T. Sakalar, D. Tural, M. A. Kaplan, O. Tanriverdi, I. Bilgetekin, and R. Uslu. The efficacy and safety analysis of the treatments of EVE and EXE combination in 101 metastatic breast cancer patients: real-life experience from Turkey. P6-18-37.

Author contributions

A. B., M. U., and S. M. were involved in the conception and design of the study. All authors were involved in acquisition, analysis and interpretation of data. All authors were involved in the writing, review, and/or revision of this manuscript. All authors have read and approved the final manuscript.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.